Halyard Health (NYSE:HYH) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday. The firm currently has a $62.00 price objective on the medical instruments supplier’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 14.62% from the company’s previous close.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
HYH has been the topic of a number of other reports. Stifel Nicolaus raised their price target on Halyard Health from $52.00 to $58.00 and gave the stock a “buy” rating in a research note on Thursday, May 3rd. KeyCorp upgraded Halyard Health from a “sector weight” rating to an “overweight” rating in a research note on Thursday, April 5th. Deutsche Bank raised their price target on Halyard Health from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, May 3rd. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research note on Wednesday, February 28th. Finally, Morgan Stanley raised their price target on Halyard Health from $48.50 to $52.00 and gave the stock an “underweight” rating in a research note on Thursday, May 3rd. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $56.80.
Shares of HYH opened at $54.09 on Thursday. The company has a current ratio of 3.22, a quick ratio of 2.96 and a debt-to-equity ratio of 0.43. Halyard Health has a 12 month low of $35.79 and a 12 month high of $54.46. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 3.40 and a beta of 1.62.
Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, May 2nd. The medical instruments supplier reported $0.76 EPS for the quarter, beating the consensus estimate of $0.17 by $0.59. The business had revenue of $156.40 million for the quarter, compared to the consensus estimate of $155.08 million. Halyard Health had a return on equity of 7.90% and a net margin of 7.72%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business posted $0.48 EPS. equities research analysts expect that Halyard Health will post 1.77 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in HYH. First Manhattan Co. raised its holdings in Halyard Health by 595.1% in the 4th quarter. First Manhattan Co. now owns 15,189 shares of the medical instruments supplier’s stock worth $701,000 after purchasing an additional 13,004 shares during the period. Swiss National Bank raised its holdings in Halyard Health by 2.3% in the 4th quarter. Swiss National Bank now owns 78,700 shares of the medical instruments supplier’s stock worth $3,634,000 after purchasing an additional 1,800 shares during the period. Fox Run Management L.L.C. bought a new position in Halyard Health in the 4th quarter worth $385,000. Suntrust Banks Inc. bought a new position in Halyard Health in the 4th quarter worth $330,000. Finally, Millennium Management LLC raised its holdings in Halyard Health by 107.7% in the 4th quarter. Millennium Management LLC now owns 215,689 shares of the medical instruments supplier’s stock worth $9,961,000 after purchasing an additional 111,849 shares during the period. Hedge funds and other institutional investors own 90.51% of the company’s stock.
Halyard Health Company Profile
Halyard Health, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.
Get a free copy of the Zacks research report on Halyard Health (HYH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.